ArticlePain medicine (Malden, Mass.)2026
Quantitative sensory testing of pain in persons with opioid use disorder on opioid agonist treatment: a scoping review.
Article in Pain medicine (Malden, Mass.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- An opioid-withholding human laboratory paradigm during opioid agonist treatment for opioid use disorder and chronic pain: Phase- and dose-dependent effects of cannabidiol.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2026Trial
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
objectiveTo evaluate the use of quantitative sensory testing (QST) in assessing pain responses and mechanisms among individuals with opioid use disorder (OUD) receiving opioid agonist treatment (OAT).
designScoping review following PRISMA-ScR guidelines.
settingSystematic literature search across 5 major databases. SUBJECTS: Studies investigating QST outcomes in adults with OUD receiving OAT (methadone, buprenorphine, or other opioid agonists) with or without co-occurring chronic pain.
methodsWe searched Ovid MEDLINE, Embase, APA PsycINFO, Cochrane Library, and Web of Science from inception through March 2025. Eligible studies included original research employing QST methodologies in adults with OUD receiving OAT. Data extraction focused on study characteristics, QST methodologies, and pain-related outcomes.
resultsOf 45 included studies, 64.4% employed cross-sectional designs with limited protocol standardization. Static QST measures predominated, with thermal stimuli most common. The most consistent finding was reduced cold pain tolerance in individuals with OUD compared to controls (60% of studies). Dynamic QST measures (3 studies) revealed altered pain modulation suggestive of central sensitization. Pain processing abnormalities frequently persisted despite prolonged abstinence from non-OAT opioids, suggesting lasting neuroadaptive changes. Methodological heterogeneity and inconsistent reporting of clinical variables limited synthesis.
conclusionsQST demonstrates potential for enhancing clinical understanding of pain mechanisms in individuals receiving OAT. Future research should prioritize protocol standardization, longitudinal designs tracking pain sensitivity changes, and exploration of QST's predictive value for treatment responses to facilitate clinical integration.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.